Previous 10 | Next 10 |
2023-04-14 09:32:33 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mind Medicine (NASDAQ: MNMD ) stock is on the rise Friday after releasing positive results from a Phase 2 clinical trial. That clinical trial saw the company testing the e...
2023-04-14 07:24:52 ET Mind Medicine ( NASDAQ: MNMD ) added 10% after announcing that an investigator-initiated mid-stage trial for a depression therapy reached the primary endpoint with a statistically significant improvement in disease symptoms. The double-blind, active-...
– Primary endpoint achieved statistically significant improvement in MDD symptoms – – Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD) – ȁ...
The next few decades will likely see psychedelic treatments go from relative obscurity to playing center stage in the psychiatric space. After decades of prohibition, psychedelics are now emerging as a potential alternative to traditional mental health therapies amid a surge in psychedelic rese...
A growing body of scientific literature has revealed that psychedelic drugs such as ketamine, MDMA and psilocybin may have therapeutic potential. Researchers have found in recent years that these hallucinogens may be able to alleviate the symptoms of certain mental health disorders when accompa...
2023-03-29 22:59:14 ET Summary Since LSD is not patentable, the company will have to find something else to generate revenue that would bolster the bottom line. With the company being a Meme stock in the past, it could present an opportunity for those getting in at an attractive e...
Psychedelics are poised to play a significant role in the evolution of the psychiatric industry . Hallucinogenics have revealed in several studies that they are capable of treating a variety of mental health disorders with minimal side effects. Researchers have found that psychedelics such a...
2023-03-09 16:35:03 ET Mind Medicine press release ( NASDAQ: MNMD ): FY GAAP EPS of -$1.84 beats by $0.46 . Cash and cash equivalents of $142.1 million at December 31, 2022. For further details see: Mind Medicine GAAP EPS of -$1.84 beats by $0.46
– Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – – Company to initiate first clinical trial of MM-402 in 2023 – – Cash and cash equivalents of $142.1 million at December 31, 202...
After decades of federal prohibition prevented the research and medical use of psychedelic drugs, the U.S. Department of Veteran Affairs is now considering opening the door to psychedelic treatments for veterans. Research in the 1960s first revealed that psychedelics had therapeutic propert...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...
Cluster headaches are headaches characterized by severe pain that often occurs on a side of the head or behind one eye. These headaches may last anywhere between 15 minutes to 3 hours and usually strike suddenly, often recurring more than once a day. The pain experienced by patients is... R...